Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › bendamustine

bendamustine

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of bendamustine

77 trials tracked of bendamustine: 17 in phase 3 or 4 and 10 with published results. The most-cited published study has 343 citations.

77Trials tracked
17Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 2 Phase 3 15 Phase 2 56 Phase 1 4
  1. Phase 3 A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) Completed · 343 cited
  2. Phase 3 A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed · 300 cited
  3. Phase 3 A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed · 258 cited
  4. Phase 3 Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) Completed · 247 cited
  5. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Completed · 210 cited
  6. Phase 3 A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a Completed · 150 cited
Show 44 more trials
  1. Phase 3 A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia Completed · 35 cited
  2. Phase 3 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Completed · 32 cited
  3. Phase 3 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Completed · 25 cited
  4. Phase 3 A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment Completed · 5 cited
  5. Phase 4 An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma Completed
  6. Phase 4 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed
  7. Phase 3 A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Completed
  8. Phase 3 A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy Completed
  9. Phase 3 A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation Completed
  10. Phase 3 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study Completed
  11. Phase 3 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed
  12. Phase 2 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Completed
  13. Phase 2 Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia Completed
  14. Phase 2 A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Completed
  15. Phase 2 Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL Completed
  16. Phase 2 Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma Completed
  17. Phase 2 Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide Completed
  18. Phase 2 Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Completed
  19. Phase 2 Optimising Renal Outcome in Myeloma Renal Failure Completed
  20. Phase 2 A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Completed
  21. Phase 2 Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed
  22. Phase 2 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed
  23. Phase 2 Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma Completed
  24. Phase 2 Bendamustine and Melphalan in Myeloma Completed
  25. Phase 2 Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Completed
  26. Phase 2 S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma Completed
  27. Phase 2 Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Completed
  28. Phase 2 Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Completed
  29. Phase 2 Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma Completed
  30. Phase 2 Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma Completed
  31. Phase 2 Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma Completed
  32. Phase 2 A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Completed
  33. Phase 2 Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Completed
  34. Phase 2 Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT) Completed
  35. Phase 2 Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL Completed
  36. Phase 2 Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) Completed
  37. Phase 2 Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age Completed
  38. Phase 2 Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer Completed
  39. Phase 2 Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy Completed
  40. Phase 2 Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma Completed
  41. Phase 2 Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) Completed
  42. Phase 2 Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Completed
  43. Phase 2 Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed
  44. Phase 2 A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL) Completed

Showing the 50 most-cited and recently-updated of 77 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Oncology RCT
Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs.
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
Apr 28, 2026
BR regimen shows survival outcomes in newly diagnosed Waldenstroms Macroglobulinemia patients
Hematology
BR regimen shows survival outcomes in newly diagnosed Waldenstroms Macroglobulinemia patients A Rare Blood Cancer With an 8-Year Survival: What Real-World Data Shows
This single-center retrospective analysis evaluated 89 newly diagnosed Waldenstroms Macroglobulinemia patients treated with the BR regimen.
New real-world data shows patients with the rare blood cancer Waldenstrom's macroglobulinemia live a median of over 8 years after diagnosis.
medRxiv Apr 16, 2026